Related to Cell Therapy Trial for Paralysis Gets FDA OK

• Geron’s Setback with Testing Its hESC Therapy in Humans Points to FDA’s Continued Cautionary Stance
  Data from animal studies prompted the clinical hold, which highlights the various kinks yet to be worked out.
  
• Examining Both Sides of the Sirtuin Coin
  Jury is still out on whether inhibition and/or activation can treat neurodegenerative disorders.
  
• Osiris’ Race to Market an FDA-Approved Stem Cell Product
  Mesenchymal stem cell therapy Prochymal is in Phase III but still has challenges to overcome.
  
• No New Parkinson Disease Drug Expected Anytime Soon
  Drugs acting on nondopaminergic systems have yet to prove their mettle in clinical trials.
  
• Changes Brewing at the FDA for Orphan Drugs
  Initiatives to de-risk drug development could include redesigning clinical trial requirements.
  
• 2011 Budget Outlook: Trim, Cut, Then Slash
  Agencies like the FDA and NIH are looking at potentially huge cuts.
  
• FDA Panel Hearing Suggests Medical Professionals May Play Role in Direct-to-Consumer Testing
  Changes including more regulation may take some time, as recommendations for the agency are yet to be finalized.
  
• NIH and FDA Taking Partnership for Regulatory and Translational Science One Step at a Time
  Over the past year, initiative named members, held two meetings, and gave out $9.4 million.
  
• A Clearer Regulatory Pathway for Cell Therapy May Help Improve Investment
  In the U.S. and the U.K., gov’t and foundations play a key funding role as investors try to avoid the risk.